Side Effects Associated with Prostaglandin Analog Therapy

被引:195
作者
Alm, Albert [2 ]
Grierson, Ian [3 ,4 ]
Shields, M. Bruce [1 ]
机构
[1] Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06510 USA
[2] Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden
[3] Univ Liverpool, St Pauls Eye Dept, Liverpool L69 3BX, Merseyside, England
[4] Univ Liverpool, Unit Ophthalmol, Liverpool L69 3BX, Merseyside, England
关键词
conjunctival hyperaemia; cysroid macular edema; iris pigmentation; prostaglandin analogs; side effects;
D O I
10.1016/j.survophthal.2008.08.004
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Topical prostaglandin analogs, which have become first-line therapy in the medical management of glaucoma, have an excellent safety profile with regard to systemic side effects, but are associated with several ocular side effects. Some of these are common, with no apparent serious consequences other than cosmetic, whereas others are much less common but represent potentially sight-threatening side effects. The former group includes conjunctival hyperemia, elongation and darkening of eyelashes, induced iris darkening, and periocular skin pigmentation. The latter group of side effects, which are relatively rare and lack definitive causal relationship to prostaglandin analog therapy, includes iris cysts, cystoid macular edema, anterior uveitis, and reactivation of herpes simplex keratitis. Most of the literature regarding side effects associated with prostaglandin analogs involves the use of latanoprost, probably because it was the first to be studied. There is no evidence, however, aside from less conjunctival hyperemia with latanoprost, that the commercially available prostaglandin analogs differ significantly with regard to side effects. (Surv Ophthalmol 53:S93-S105, 2008. (C) 2008 Elsevier Inc. All rights reserved.)
引用
收藏
页码:S93 / S105
页数:13
相关论文
共 140 条
  • [1] ABDELMALEK ZA, 1987, CANCER RES, V47, P3141
  • [2] Albert Daniel M, 2003, Trans Am Ophthalmol Soc, V101, P217
  • [3] A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients
    Albert, DM
    Gangnon, RE
    Zimbric, ML
    Damico, CM
    Fisher, MR
    Gleiser, J
    Grossniklaus, HE
    Green, WR
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2004, 122 (11) : 1680 - 1685
  • [4] Albert DM, 2003, T AM OPHTHAL SOC, V101, P221
  • [5] A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma
    Alm, A
    Schoenfelder, J
    McDermott, J
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2004, 122 (07) : 957 - 965
  • [6] PHXA34, A NEW POTENT OCULAR HYPOTENSIVE DRUG - A STUDY ON DOSE-RESPONSE RELATIONSHIP AND ON AQUEOUS-HUMOR DYNAMICS IN HEALTHY-VOLUNTEERS
    ALM, A
    VILLUMSEN, J
    [J]. ARCHIVES OF OPHTHALMOLOGY, 1991, 109 (11) : 1564 - 1568
  • [7] Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning - A comparison with timolol
    Alm, A
    Stjernschantz, J
    Widengard, I
    Linden, C
    Soderstrom, M
    Nilsson, SE
    Fristrom, B
    Lindblom, B
    Heijl, A
    Gundersen, KG
    Ehinger, B
    Holmin, C
    BengtssonStigmar, E
    Aasved, H
    Jangard, P
    Ringvold, A
    Vegge, T
    Halseide, R
    LundAndersen, H
    Flesner, P
    Thygesen, J
    Airaksinen, J
    Tuulonen, A
    [J]. OPHTHALMOLOGY, 1995, 102 (12) : 1743 - 1752
  • [8] [Anonymous], AM J OPHTHALMOL
  • [9] Analysis of irises with a latanoprost-induced change in iris color
    Arranz-Marquez, E
    Teus, MA
    Saornil, MA
    Mendez, MC
    Gil, R
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 138 (04) : 625 - 630
  • [10] Effect of age on the development of a latanoprost-induced increase in iris pigmentation
    Arranz-Marquez, Esther
    Teus, Miguel A.
    [J]. OPHTHALMOLOGY, 2007, 114 (07) : 1255 - 1258